Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plus Therapeutics, Inc. (NASDAQ: PSTV) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering investors a structured view of its financial condition, capital structure, governance, and clinical-stage operations. As a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and CNS cancer diagnostics, Plus Therapeutics uses SEC reports to describe its business, risks, and material events.
Core filings such as the Form 10-K annual report and Form 10-Q quarterly reports provide detailed discussions of the company’s radiotherapeutic pipeline, including REYOBIQ™ (rhenium Re186 obisbemeda), its CNSide Diagnostics subsidiary, grant funding, and liquidity. These documents also outline risk factors related to clinical development, regulatory approvals, Nasdaq listing standards, and capital needs.
Frequent Form 8-K current reports disclose material events, including Nasdaq notices about minimum bid price and stockholders’ equity compliance, extensions to regain listing compliance, purchase agreements with institutional investors, public offerings of common stock and warrants, and significant lease or financing arrangements. Proxy materials on Schedule 14A describe board elections, stock incentive plans, reverse stock split authority, and stockholder voting outcomes.
On this page, Stock Titan enhances access to these filings with AI-powered summaries that explain key points in plain language, helping users quickly understand complex documents such as registration statements on Form S-1, equity purchase agreements, or governance-related filings. Real-time integration with the SEC’s EDGAR system ensures new Plus Therapeutics filings appear promptly.
Investors can also use this section to monitor potential insider activity reported on ownership forms, as well as to follow any future proxy statements addressing compensation or capital structure changes. By combining raw filings with AI-generated highlights, the page is designed to make Plus Therapeutics’ regulatory history and ongoing disclosure record more accessible to both experienced and newer market participants.
Plus Therapeutics is a U.S. healthcare company focused on precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. Its lead drug, rhenium (186Re) obisbemeda, is being tested in recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancers, with Fast Track and multiple orphan drug designations.
The company is also commercializing its CNSide cerebrospinal fluid assay platform through wholly owned CNSide Diagnostics. The CNSide Test was reintroduced in August 2025, supported by a CLIA-accredited lab in Houston and national agreements with UnitedHealthcare and Humana that expand access to more than 67 million covered lives.
Development is heavily supported by non‑dilutive funding, including a CPRIT grant of up to $17.6 million for leptomeningeal metastases (about $15.9 million received by December 31, 2025), an active $3.0 million NIH/NCI award for glioblastoma and a $3.0 million Department of Defense award for pediatric brain cancer. As of March 10, 2026, there were 171,550,698 shares of common stock outstanding.
Plus Therapeutics reported 2025 results that combine larger losses with a much stronger balance sheet and strategic progress in CNS cancer programs. Grant revenue was $5.2 million for the year, while net loss widened to $22.4 million, or $(0.29) per basic share, compared with a $13.0 million loss in 2024.
Cash, cash equivalents and investments rose to $13.1 million as of December 31, 2025, up from $3.6 million a year earlier, helped by an upsized public offering that generated $15 million in gross proceeds and additional equity sales. The company is prioritizing CNSide commercial scale-up and pivotal trial readiness for its REYOBIQ radiotherapeutic.
Operationally, Plus Therapeutics secured an AMA Category III CPT code for REYOBIQ delivery, expanded CNSide laboratory licensing to 49 U.S. states, and added national coverage agreements that extend CNSide test policy coverage to about 67 million people. For 2026, it targets key REYOBIQ clinical milestones, expanded payer coverage to more than 150 million covered lives, and CNSide Diagnostics breakeven by 2027.
PLUS THERAPEUTICS, INC. reported that Chief Financial Officer Andrew John Hugh MacIntyre acquired equity awards consisting of restricted stock units and stock options. He received 349,542 Restricted Stock Units, each representing a contingent right to one share of common stock, and 349,541 stock options with a right to buy common stock.
The RSUs vest in substantially equal 1/12th increments over twelve quarters, beginning on April 1, 2026 with the remaining portions vesting quarterly thereafter. The options vest over four years in substantially equal 1/48th monthly increments on each monthly anniversary of grant and also vest upon a change of control in accordance with his employment agreement.
HEDRICK MARC H reported acquisition or exercise transactions in this Form 4 filing.
PLUS Therapeutics reported that Chief Executive Officer Marc H. Hedrick received new equity awards. He was granted 2,419,582 Restricted Stock Units, each representing one share of common stock, and 2,419,582 stock options with a right to buy common shares.
The RSUs vest in twelve equal quarterly installments, starting with the first 1/12th on April 1, 2026 and continuing quarterly thereafter. The stock options vest in 48 equal monthly installments over four years, and also vest upon a change of control as provided in his employment agreement.
Plus Therapeutics updated its executive pay disclosure by adding 2025 discretionary cash bonuses for its named executive officers. The Compensation Committee approved these bonuses on February 9, 2026, completing the previously incomplete 2025–2024 summary compensation table originally referenced in a Form S-1 registration statement.
For 2025, President and CEO Marc H. Hedrick, M.D. received total compensation of $5,566,732, including a $585,000 salary, option awards valued at $3,531,841, restricted stock awards of $1,100,647, non-equity incentive plan compensation of $305,663, and other compensation of $43,581. Chief Financial Officer Andrew Sims received 2025 total compensation of $1,631,279, including a $390,000 salary, option awards of $810,388, restricted stock awards of $264,154, non-equity incentive plan compensation of $149,175, and other compensation of $17,562. Former Chief Medical Officer Norman LaFrance, M.D., who stepped down on June 11, 2024, shows no 2025 compensation, with 2024 total compensation of $285,912.
CVI Investments, Inc. and Heights Capital Management, Inc. filed a Schedule 13G reporting beneficial ownership of 12,368,423 shares of Plus Therapeutics, Inc. common stock, representing 6.9% of the outstanding shares. All reported shares are held with shared voting and shared dispositive power, with no sole voting or dispositive authority. Heights Capital Management acts as investment manager to CVI Investments and may be deemed a beneficial owner, but both parties disclaim beneficial ownership beyond their pecuniary interest. The ownership percentage is based on 178,371,232 shares outstanding as indicated in a Plus Therapeutics prospectus filed on January 14, 2026. The filers certify that the securities are held without the purpose or effect of changing or influencing control of Plus Therapeutics.
Plus Therapeutics, Inc. filed a current report noting that it has updated its corporate investor presentation for use in meetings with investors, analysts, and other stakeholders. The updated materials are provided as an exhibit labeled an investor presentation as of January 22, 2026.
The company indicates that these slides are intended to support discussions about its business with the financial community and others by providing a refreshed overview in a single document.
Plus Therapeutics, Inc. completed an underwritten public offering of 39,473,684 shares of common stock and 39,473,684 warrants at a combined public offering price of $0.38 per share and warrant, generating approximately $13.3 million in net proceeds after underwriting discounts, commissions and expenses. The company also granted the underwriter a 30-day option to buy up to an additional 5,921,052 shares, additional warrants to purchase up to 5,921,052 shares, or a combination, and the underwriter exercised this option for additional warrants to purchase 5,921,052 shares. Each warrant is immediately exercisable at $0.38 per share and expires five years from issuance, and the company expects to use the net proceeds for working capital and general corporate purposes. The company and its directors and executive officers agreed to 45-day lock-up restrictions, and the company agreed to avoid variable rate transactions for 120 days after the final prospectus date.